Search | Clinical Trials Finder

Conditions: Cognitive Decline, Dementia, Vascular, Alzheimer Disease, Dementia, Stroke
Interventions: Behavioral Dietary intervention ( MIND Diet), Behavioral Usual Care Diet Intervention; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome, Prenatal Benign Hypophosphatasia, Perinatal Lethal Hypophosphatasia, Odontohypophosphatasia, Adult Hypophosphatasia, Childhood-onset Hypophosphatasia, Infantile Hypophosphatasia, Hypophosphatasia, Kabuki Syndrome, Bohring-Opitz Syndrome, Narcolepsy Without Cataplexy, Narcolepsy-cataplexy, Hypersomnolence Disorder, Idiopathic Hypersomnia Without Long Sleep Time, Idiopathic Hypersomnia With Long Sleep Time, Idiopathic Hypersomnia, Kleine-Levin Syndrome, Kawasaki Disease, Leiomyosarcoma, Leiomyosarcoma of the Corpus Uteri, Leiomyosarcoma of the Cervix Uteri, Leiomyosarcoma of Small Intestine, Acquired Myasthenia Gravis, Addison Disease, Hyperacusis (Hyperacousis), Juvenile Myasthenia Gravis, Transient Neonatal Myasthenia Gravis, Williams Syndrome, Lyme Disease, Myasthenia Gravis, Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome), Isolated Klippel-Feil Syndrome, Frasier Syndrome, Denys-Drash Syndrome, Beckwith-Wiedemann Syndrome, Emanuel Syndrome, Isolated Aniridia, Axenfeld-Rieger Syndrome, Aniridia-intellectual Disability Syndrome, Aniridia - Renal Agenesis - Psychomotor Retardation, Aniridia - Ptosis - Intellectual Disability - Familial Obesity, Aniridia - Cerebellar Ataxia - Intellectual Disability, Aniridia - Absent Patella, Aniridia, Peters Anomaly - Cataract, Peters Anomaly, Potocki-Shaffer Syndrome, Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11, Silver-Russell Syndrome Due to Imprinting Defect of 11p15, Silver-Russell Syndrome Due to 11p15 Microduplication, Syndromic Aniridia, WAGR Syndrome, Wolf-Hirschhorn Syndrome, 4p16.3 Microduplication Syndrome, 4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome, Autosomal Recessive Stickler Syndrome, Stickler Syndrome Type 2, Stickler Syndrome Type 1, Stickler Syndrome, Mucolipidosis Type 4, X-linked Spinocerebellar Ataxia Type 4, X-linked Spinocerebellar Ataxia Type 3, X-linked Intellectual Disability - Ataxia - Apraxia, X-linked Progressive Cerebellar Ataxia, X-linked Non Progressive Cerebellar Ataxia, X-linked Cerebellar Ataxia, Vitamin B12 Deficiency Ataxia, Toxic Exposure Ataxia, Unclassified Autosomal Dominant Spinocerebellar Ataxia, Thyroid Antibody Ataxia, Sporadic Adult-onset Ataxia of Unknown Etiology, Spinocerebellar Ataxia With Oculomotor Anomaly, Spinocerebellar Ataxia With Epilepsy, Spinocerebellar Ataxia With Axonal Neuropathy Type 2, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 5, Spinocerebellar Ataxia Type 4, Spinocerebellar Ataxia Type 37, Spinocerebellar Ataxia Type 36, Spinocerebellar Ataxia Type 35, Spinocerebellar Ataxia Type 34, Spinocerebellar Ataxia Type 32, Spinocerebellar Ataxia Type 31, Spinocerebellar Ataxia Type 30, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 29, Spinocerebellar Ataxia Type 28, Spinocerebellar Ataxia Type 27, Spinocerebellar Ataxia Type 26, Spinocerebellar Ataxia Type 25, Spinocerebellar Ataxia Type 23, Spinocerebellar Ataxia Type 22, Spinocerebellar Ataxia Type 21, Spinocerebellar Ataxia Type 20, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 19/22, Spinocerebellar Ataxia Type 18, Spinocerebellar Ataxia Type 17, Spinocerebellar Ataxia Type 16, Spinocerebellar Ataxia Type 15/16, Spinocerebellar Ataxia Type 14, Spinocerebellar Ataxia Type 13, Spinocerebellar Ataxia Type 12, Spinocerebellar Ataxia Type 11, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 1 With Axonal Neuropathy, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia - Unknown, Spinocerebellar Ataxia - Dysmorphism, Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature, Spasticity-ataxia-gait Anomalies Syndrome, Spastic Ataxia With Congenital Miosis, Spastic Ataxia - Corneal Dystrophy, Spastic Ataxia, Rare Hereditary Ataxia, Rare Ataxia, Recessive Mitochondrial Ataxia Syndrome, Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature, Posterior Column Ataxia - Retinitis Pigmentosa, Post-Stroke Ataxia, Post-Head Injury Ataxia, Post Vaccination Ataxia, Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract, Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus, Non-hereditary Degenerative Ataxia, Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity, Olivopontocerebellar Atrophy - Deafness, NARP Syndrome, Myoclonus - Cerebellar Ataxia - Deafness, Multiple System Atrophy, Parkinsonian Type, Multiple System Atrophy, Cerebellar Type, Multiple System Atrophy, Maternally-inherited Leigh Syndrome, Machado-Joseph Disease Type 3, Machado-Joseph Disease Type 2, Machado-Joseph Disease Type 1, Leigh Syndrome, Late-onset Ataxia With Dementia, Infection or Post Infection Ataxia, GAD Ataxia, Hereditary Episodic Ataxia, Gliadin/Gluten Ataxia, Friedreich Ataxia, Fragile X-associated Tremor/Ataxia Syndrome, Familial Paroxysmal Ataxia, Exposure to Medications Ataxia, Episodic Ataxia With Slurred Speech, Episodic Ataxia Unknown Type, Episodic Ataxia Type 7, Episodic Ataxia Type 6, Episodic Ataxia Type 5, Episodic Ataxia Type 4, Episodic Ataxia Type 3, Episodic Ataxia Type 1, Epilepsy and/or Ataxia With Myoclonus as Major Feature, Early-onset Spastic Ataxia-neuropathy Syndrome, Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity, Early-onset Cerebellar Ataxia With Retained Tendon Reflexes, Early-onset Ataxia With Dementia, Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia, Dilated Cardiomyopathy With Ataxia, Cataract - Ataxia - Deafness, Cerebellar Ataxia, Cayman Type, Cerebellar Ataxia With Peripheral Neuropathy, Cerebellar Ataxia - Hypogonadism, Cerebellar Ataxia - Ectodermal Dysplasia, Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss, Brain Tumor Ataxia, Brachydactyly - Nystagmus - Cerebellar Ataxia, Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia, Autosomal Recessive Syndromic Cerebellar Ataxia, Autosomal Recessive Spastic Ataxia With Leukoencephalopathy, Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay, Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria, Autosomal Recessive Spastic Ataxia, Autosomal Recessive Metabolic Cerebellar Ataxia, Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine, Autosomal Recessive Ataxia, Beauce Type, Autosomal Recessive Ataxia Due to Ubiquinone Deficiency, Autosomal Recessive Ataxia Due to PEX10 Deficiency, Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia, Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency, Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency, Autosomal Recessive Congenital Cerebellar Ataxia, Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome, Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency, Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency, Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency, Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome, Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity, Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency, Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect, Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion, Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation, Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness, Autosomal Recessive Cerebellar Ataxia, Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly, Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation, Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy, Autosomal Dominant Spastic Ataxia Type 1, Autosomal Dominant Spastic Ataxia, Autosomal Dominant Optic Atrophy, Ataxia-telangiectasia Variant, Ataxia-telangiectasia, Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy, Autosomal Dominant Cerebellar Ataxia Type 4, Autosomal Dominant Cerebellar Ataxia Type 3, Autosomal Dominant Cerebellar Ataxia Type 2, Autosomal Dominant Cerebellar Ataxia Type 1, Autosomal Dominant Cerebellar Ataxia, Ataxia-telangiectasia-like Disorder, Ataxia With Vitamin E Deficiency, Ataxia With Dementia, Ataxia - Oculomotor Apraxia Type 1, Ataxia - Other, Ataxia - Genetic Diagnosis - Unknown, Acquired Ataxia, Adult-onset Autosomal Recessive Cerebellar Ataxia, Alcohol Related Ataxia, Multiple Endocrine Neoplasia, Multiple Endocrine Neoplasia Type II, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Multiple Endocrine Neoplasia, Type IV, Multiple Endocrine Neoplasia, Type 3, Multiple Endocrine Neoplasia (MEN) Syndrome, Multiple Endocrine Neoplasia Type 2B, Multiple Endocrine Neoplasia Type 2A, Atypical Hemolytic Uremic Syndrome, Atypical HUS, Wiedemann-Steiner Syndrome, Breast Implant-Associated Anaplastic Large Cell Lymphoma, Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA), Hemophagocytic Lymphohistiocytosis, Behcet's Disease, Alagille Syndrome, Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD), Lowe Syndrome, Pitt Hopkins Syndrome, 1p36 Deletion Syndrome, Jansen Type Metaphyseal Chondrodysplasia, Cockayne Syndrome, Chronic Recurrent Multifocal Osteomyelitis, CRMO, Malan Syndrome, Hereditary Sensory and Autonomic Neuropathy Type Ie, VCP Disease, Hypnic Jerking, Sleep Myoclonus, Mollaret Meningitis, Recurrent Viral Meningitis, CRB1, Leber Congenital Amaurosis, Retinitis Pigmentosa, Rare Retinal Disorder, KCNMA1-Channelopathy, Primary Biliary Cirrhosis, ZMYND11, Transient Global Amnesia, Glycogen Storage Disease, Alstrom Syndrome, White Sutton Syndrome, DNM1, EIEE31, Myhre Syndrome, Recurrent Respiratory Papillomatosis, Laryngeal Papillomatosis, Tracheal Papillomatosis, Refsum Disease, Nicolaides Baraitser Syndrome, Leukodystrophy, Tango2, Cauda Equina Syndrome, Rare Gastrointestinal Disorders, Achalasia-Addisonian Syndrome, Achalasia Cardia, Achalasia Icrocephaly Syndrome, Anal Fistula, Congenital Sucrase-Isomaltase Deficiency, Eosinophilic Gastroenteritis, Idiopathic Gastroparesis, Hirschsprung Disease, Rare Inflammatory Bowel Disease, Intestinal Pseudo-Obstruction, Scleroderma, Short Bowel Syndrome, Sacral Agenesis, Sacral Agenesis Syndrome, Caudal Regression, Scheuermann Disease, SMC1A Truncated Mutations (Causing Loss of Gene Function), Cystinosis, Juvenile Nephropathic Cystinosis, Nephropathic Cystinosis, Kennedy Disease, Spinal Bulbar Muscular Atrophy, Warburg Micro Syndrome, Mucolipidoses, Mitochondrial Diseases, Mitochondrial Aminoacyl-tRNA Synthetases, Mt-aaRS Disorders, Hypertrophic Olivary Degeneration, Non-Ketotic Hyperglycinemia, Fish Odor Syndrome, Halitosis, Isolated Congenital Asplenia, Lambert Eaton (LEMS), Biliary Atresia, STAG1 Gene Mutation, Coffin Lowry Syndrome, Borjeson-Forssman-Lehman Syndrome, Blau Syndrome, Arginase 1 Deficiency, HSPB8 Myopathy, Beta-Mannosidosis, TBX4 Syndrome, DHDDS Gene Mutations, MAND-MBD5-Associated Neurodevelopmental Disorder, Constitutional Mismatch Repair Deficiency (CMMRD), SPATA5 Disorder, SPATA5L1 Related Disorder, Acrodysostosis, Multi-systematic Smooth Muscle Dysfunction Syndrome, CRELD1 (Cysteine Rich With EGF Like Domains 1), GNB1 Syndrome, Pyruvate Dehydrogenase Complex Deficiency Disease, Beta Mannosidosis, Kbg Syndrome, Labrune Syndrome, Metachromatic Leukodystrophy (MLD), Moyamoya Disease, OPHN1 Syndrome, Oculopharyngeal Muscular Dystrophy (OPMD), TUBB3 Mutation, WOREE (WWOX-related Epileptic Encephalopathy, SCAR12, Skraban-Deardorff Syndrome, Hereditary Myopathy With Early Respiratory Failure, Parry Romberg Syndrome, Lesch-Nyhan Disease, GNB1 Gene Mutation, Pierpont Syndrome, TBL1XR1 Gene Variant, Activated PI3K Delta Syndrome (APDS), Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP), Brain Abnormalities, Neurodegeneration, and Dysosteosclerosis, CSF1R Related Disease (CSF1R-RD), Hereditary Diffuse Leukoencephalopathy With Axonal Spheroids and Pigmented Glia, Nasu-Hakola Disease
Interventions: Not listed
Lead sponsor: Sanford Health; Other
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2100
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Cognitive Decline, Dementia, Alzheimer Disease, Vascular Dementia
Interventions: MIND Diet, Mild Weight Loss; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 65 Years to 84 Years
Enrollment: 604 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Memory Disorders, Alzheimer's Disease
Interventions: Aricept, IFN-alpha2A; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mixed, Dementia, Mild, Dementia of Alzheimer Type, Mild Cognitive Impairment, Mild Dementia
Interventions: SmartPrompt smartphone application; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions: Palliative Care; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 105 Years
Enrollment: 783 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions: Care Coordination; Behavioral
Lead sponsor: Mathematica Policy Research, Inc.; Other
Eligibility: Not listed
Enrollment: 18,277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 15
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more

Conditions: Brain Health, Gestational Hypertension, Alzheimer Disease, Dementia, Cardiovascular Diseases, Pregnancy Related, Pre-Eclampsia
Interventions: A combination of various tests and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy on brain health in midlife.; Diagnostic Test
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions: Retinal and Choroidal Imaging; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions: Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group; Drug · Dietary Supplement
Lead sponsor: Michal Schnaider Beeri, Ph.D.; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Alzheimer Disease, Cerebral Amyloid Angiopathy
Interventions: EVOO, OO; Other
Lead sponsor: Auburn University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Hypertension, Hypercholesterolemia, Dementia Risk Factors
Interventions: Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 50 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dementia-related Psychosis
Interventions: Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 27
States / cities: Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more

Conditions: Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction, Executive Dysfunction
Interventions: Omega 3 PUFA, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 75 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Dementia, Dementia, Vascular, Alzheimer Disease, Dementia, Mixed
Interventions: The BRAIN App; Behavioral
Lead sponsor: Hopeful Aging; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Winchester, Massachusetts

Conditions: Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease, Stroke, Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aliso Viejo, California

Conditions: Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Interventions: ECHS AD Device; Device
Lead sponsor: Herrick Medical LLC; Industry
Eligibility: 50 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Stroke, Hypertension, Diabete Mellitus, Dyslipidemias, Sleep Disorder, Smoking, Overweight and Obesity, Familial Alzheimer Disease, Atrial Fibrillation, Cardiac Disease, Cognitive Impairment, Transient Ischemic Attack
Interventions: DELPhI system; Device
Lead sponsor: QuantalX Neuroscience; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Walnut Creek, California • Atlanta, Georgia • Norwood, Ohio

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions: Angiotensin 1-7, Saline solution; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 45 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Phoenix, Arizona • Tucson, Arizona

Conditions: Aphasia, Primary Progressive Aphasia, Stroke
Interventions: EEG Neurofeedback, Sham Feedback; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma, Polytrauma, Traumatic Brain Injury, ICU, Critical Illness
Interventions: Non-interventional observational prospective cohort study; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dementia, Vascular, Stroke Sequelae
Interventions: Home telerehabilitation therapy; Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 110 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
Interventions: Nuedexta (DM 20 mg/Q 10 mg); Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: Traumatic Brain Injury, Cognitive Decline, Vascular Dementia
Interventions: No intervention. This is an observational study.; Other
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 74 Years
Enrollment: 300 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

MIND Diet Intervention and Cognitive Decline

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

Feasibility of the SmartPrompt for Improving Everyday Function in Dementia

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

Evaluation of Programs of Coordinated Care and Disease Management

Brain Health in Midlife

Retinal Imaging in Neurodegenerative Disease

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)

Vascular Intervention Strategies Trial for Alzheimer's

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

n-3 PUFA for Vascular Cognitive Aging

The BRAIN App: Building Relationships Using Artificial Intelligence and Nostalgia

PRISM Registry: Pseudobulbar Affect Registry Series

Pulsed Electromagnetic Field Treatment With Dementia Patients

DELPHI in Subjects at Risk for Stroke and Dementia

Biomarker Study: Heart Failure Patients at Risk

Circuitry Assessment and Reinforcement Training Effects on Recovery

Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study

Home Tele Rehabilitation Therapy for Vascular Dementia

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

Cognitive and Vascular Functioning Following TBI